Understanding how tumor metabolism affects T cell therapy in lymphoma
Exploiting tumor metabolism to optimize T cell therapy
This study is looking at how T-cells, which are important for fighting cancer, can be made more effective in treating diffuse large B-cell lymphoma (DLBCL) by understanding how cancer cells hide from the immune system and how changing the way tumors use energy might help.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10978685 on NIH RePORTER |
What this research studies
This research investigates the role of T-cell responses in immunotherapy for diffuse large B-cell lymphoma (DLBCL), a common type of cancer in adults. The study aims to uncover how cancer cells evade immune responses and how modifying tumor metabolism can enhance the effectiveness of T-cell therapy. By utilizing advanced imaging techniques and cancer models, the research seeks to identify molecular mechanisms that contribute to therapy resistance and explore novel treatment combinations. Patients may benefit from insights that could lead to improved immunotherapy strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with diffuse large B-cell lymphoma, particularly those who have shown resistance to standard treatments.
Not a fit: Patients with other types of lymphoma or those who do not have diffuse large B-cell lymphoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for patients with diffuse large B-cell lymphoma.
How similar studies have performed: Previous studies have shown promise in using metabolic modulation to enhance immunotherapy responses, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Serganova, Inna — Weill Medical Coll of Cornell Univ
- Study coordinator: Serganova, Inna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.